Table 1 Clinical parameters before and after propensity score matching (model 1).
Before matching | After matching (model 1) | |||||
|---|---|---|---|---|---|---|
Treatment (n = 13) | Control (n = 38) | Stand diff | Treatment (n = 13) | Control (n = 13) | Stand diff | |
*Age at inclusion, years | 48.2 ± 14.0 | 54.8 ± 17.3 | −0.42 | 48.2 ± 14.0 | 51.3 ± 17.2 | −0.20 |
*Sex prevalence, no. of men % | 7, 54% | 25, 68% | −0.28 | 7, 54% | 9, 69% | 0.32 |
*eGFR at inclusion, ml/min/1.73 m2 | 86 ± 23 | 76 ± 17 | 0.49 | 86 ± 23 | 85 ± 11 | 0.09 |
*Urinary protein at inclusion, g/gCre | 0.07 ± 0.12 | 0.12 ± 0.35 | −0.19 | 0.07 ± 0.12 | 0.05 ± 0.07 | 0.20 |
Age at onset, years | 31.1 ± 19.0 | 38.7 ± 19.0 | −0.40 | 31.1 ± 19.0 | 35.0 ± 20.0 | −0.20 |
Disease duration, months | 205 ± 114 | 192 ± 156 | 0.09 | 205 ± 114 | 197 ± 112 | 0.09 |
Past relaplse, times | 4.2 ± 3.3 | 2.7 ± 4.1 | 0.38 | 4.2 ± 3.3 | 4.3 ± 5.0 | −0.04 |
*past relapse per year, times/yr | 0.29 ± 0.19 | 0.15 ± 0.19 | 0.72 | 0.29 ± 0.19 | 0.27 ± 0.25 | 0.10 |
*Follow up period, months | 44.6 ± 4.8 | 56.6 ± 10.2 | −1.50 | 44.6 ± 4.8 | 54.7 ± 12.4 | −1.07 |
*Other immunosupressants, no./% | 6, 46% | 10, 27% | 0.41 | 6, 46% | 7, 54% | −0.15 |
*Comcomitant allergic disorders, no./% | 13, 100% | 20, 54% | 1.30 | 13, 100% | 13, 100% | 0.00 |
Dyslipedemia, no./% | 1, 8% | 14, 38% | −0.77 | 1, 8% | 2, 15% | −0.24 |
*minimum PSL dose, mg | 0.83 ± 1.1 | 2.6 ± 2.9 | −0.37 | 0.83 ± 1.1 | 1.08 ± 2.7 | −0.12 |
*PSL dose at baseline, mg | 4.1 ± 3.7 | 3.3 ± 3.7 | 0.21 | 4.1 ± 3.7 | 4.1 ± 3.8 | 0.00 |
IgE, U/mL | 780 ± 643 | 496 ± 592 | 0.46 | 780 ± 643 | 865 ± 676 | −0.13 |
Eosinophil,/microL | 80 ± 62 | 224 ± 198 | −0.98 | 80 ± 62 | 258 ± 200 | −1.20 |
Infection, irregular PSL reduction, or malignancy, no./% | 4, 31% | 16, 42% | −0.26 | 4, 31% | 3, 23% | 0.17 |
